Welcome to our dedicated page for Aptinyx news (Ticker: APTX), a resource for investors and traders seeking the latest updates and insights on Aptinyx stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aptinyx's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aptinyx's position in the market.
Aptinyx Inc. (NASDAQ: APTX) will host a conference call and webcast on March 23, 2022, at 5:00 p.m. ET to discuss Q4 and full year 2021 financial results and recent business updates. Investors can participate by dialing (844) 200-6205 domestically or (929) 526-1599 internationally, using conference ID 768426. The event will also be accessible via their website. Aptinyx is focused on developing therapies for brain and nervous system disorders with three candidates in clinical development.
Aptinyx Inc. (Nasdaq: APTX), a biopharmaceutical company, announced that CEO Andy Kidd will join the Neuropsychiatry Panel discussion at the 42nd Annual Cowen Health Care Conference on March 7, 2022, at 9:10 a.m. EST. A live webcast of the panel can be accessed on Aptinyx's website and will be available for 30 days post-event. The company focuses on developing small molecules to treat brain and nervous system disorders and has several candidates in clinical development for conditions like chronic pain and PTSD.
Aptinyx Inc. (Nasdaq: APTX) has successfully completed enrollment of 305 patients in its Phase 2b study of NYX-2925, targeting fibromyalgia. This study aims to evaluate the efficacy and safety of NYX-2925, with primary endpoints focusing on pain reduction over 12 weeks. The company anticipates reporting results in early to mid 3Q 2022. Previous studies suggest NYX-2925 may effectively alleviate fibromyalgia symptoms, enhancing patient quality of life.
Aptinyx Inc. (APTX) hosted a virtual portfolio review to discuss its NMDA receptor modulators, focusing on NYX-2925 for chronic pain. Currently in Phase 2b trials for diabetic peripheral neuropathy and fibromyalgia, NYX-2925 has shown promise in pain alleviation with a favorable safety profile. The company is also advancing NYX-783 for PTSD, with two Phase 2b trials planned. NYX-458 is under evaluation for cognitive impairment in Parkinson's patients. APTX expects data releases from these programs in the coming months.
Aptinyx Inc. (Nasdaq: APTX), a biopharmaceutical company focused on treatments for brain disorders, announced that CEO Andy Kidd will participate in a virtual fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on February 17, 2022, at 10:40 a.m. ET. The event will be available for live viewing and archived on their website for 30 days. Aptinyx is advancing a pipeline of NMDA receptor modulators aimed at conditions like chronic pain and PTSD, showcasing its innovative approach to enhancing neural communication.
Aptinyx Inc. (NASDAQ: APTX) has established a Scientific Advisory Board (SAB) comprised of leading experts in neuropsychiatry, neurology, and chronic pain. The SAB will collaborate with Aptinyx's management to enhance the understanding and therapeutic applications of its NMDA receptor modulation platform. Notable members include Chadi Abdallah and Lesley Arnold, among others. This strategic move is expected to strengthen Aptinyx's research and development efforts, potentially leading to advancements in therapies for brain and nervous system disorders.
Aptinyx Inc. (APTX) has announced significant developments for 2022, focusing on their Phase 2 studies for chronic pain, cognitive impairment, and PTSD. Key milestones include data readouts for NYX-2925 in chronic pain and NYX-458 for cognitive issues expected in mid-2022 and the second half of the year, respectively. The company has a strong financial position with approximately $106 million in cash, sufficient to fund ongoing studies and operations through 2023. Aptinyx aims to establish itself as a leading neuroscience firm with transformative therapies for serious nervous system disorders.
Aptinyx Inc. (Nasdaq: APTX) will host a virtual event on February 9, 2022, from 10:00 a.m. to 11:30 a.m. ET, focusing on its clinical pipeline.
The session will emphasize NYX-2925, a drug for chronic pain, with a presentation by Dr. Richard Rauck. The company expects to report data from its Phase 2b study of NYX-2925 for painful diabetic peripheral neuropathy in the second quarter of 2022. The event will include Q&A sessions, allowing investors to engage with the management team.
Aptinyx Inc. has commenced a Phase 2b study for NYX-783, evaluating its efficacy in 300 PTSD patients, following positive results from a Phase 2a trial. This study is positioned for registration-supportive consideration based on FDA guidance. It aims to address the significant need for new PTSD treatments, with data expected in the latter half of 2023. NYX-783, a novel NMDA receptor modulator, has shown promising safety and efficacy in preliminary studies, marking a potential breakthrough in PTSD therapy.
Aptinyx Inc. (NASDAQ: APTX) announced that CEO Andy Kidd will present at the 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022, at 12:00 p.m. PT in San Francisco, California. A live webcast of the presentation will be accessible on the company's website and archived for 30 days. Aptinyx is a clinical-stage biopharmaceutical company focused on developing therapies for brain and nervous system disorders. The company is advancing multiple product candidates targeting chronic pain, PTSD, and cognitive impairment, utilizing its proprietary synthetic small molecule platform.
